HomeAI · summaries
Storia in 7 fonti
Abivax share plunge may change deal outlook
The drugmaker has been viewed as a near-term takeover target for Big Pharma.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
AbiVax falls as safety worries cloud ‘landmark’ immune drug results
A handful of cancer cases reported among treatment recipients overshadowed efficacy results analysts described as “best-in-disease” and sent shares down more than 30%.
- ·
cnbc.com
Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
Shares of French biotech Abivax tumbled 32% after it reported fresh data on its lead asset.
- ·
zerohedge.com
Abivax Crashes Most On Record After Cancer Cases In Trial Data Spooks Wall Street
"The cancer signal complicates matters."
- ·
qz.com
Abivax stock plunges on cancer signal in ulcerative colitis trial
Jefferies downgraded the French biotech to Hold and cut its price target nearly in half, warning the cancer overhang won't resolve quickly
- ·
axios.com
Abivax share plunge may change deal outlook
The drugmaker has been viewed as a near-term takeover target for Big Pharma.
- ·
morningstar.com
Abivax Investigation Initiated: SueWallSt Investigates the Officers and Directors of Abivax (ABVX)
Abivax Investigation Initiated: SueWallSt Investigates the Officers and Directors of Abivax (ABVX)
- ·
benzinga.com
What's Going On With Abivax Stock On Thursday? - Abivax (NASDAQ:ABVX)
Abivax's Phase 3 ulcerative colitis data met remission goals, but cancer cases in the study raised safety questions and analyst caution.